Trial Profile
A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
Status:
Not yet recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary)
- Indications Central serous chorioretinopathy
- Focus Therapeutic Use
- 20 Aug 2014 New trial record